Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at Wedbush upped their Q1 2016 EPS estimates for shares of Celldex Therapeutics in a report released on Monday, according to Zacks Investment Research. Wedbush analyst D. Nierengarten now expects that the firm will earn ($0.35) per share for the quarter, up from their previous estimate of ($0.38). Wedbush […]
